X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies.
Lead Product(s): HTL0039732,Atezolizumab
Therapeutic Area: Oncology Product Name: HTL0039732
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Sosei Heptares
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
AST-VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells.
Lead Product(s): AST-VAC2
Therapeutic Area: Oncology Product Name: AST-VAC2
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Lineage Cell Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.
Lead Product(s): HTL0039732
Therapeutic Area: Oncology Product Name: HTL0039732
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Sosei Group Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 22, 2022
Details:
Following the option exercise, IDEAYA holds exclusive worldwide license rights covering a broad class of PARG inhibitors. IDEAYA owns all commercial rights in IDE161, subject to economic obligations, worldwide license with Cancer Research UK and University of Manchester.
Lead Product(s): IDE161
Therapeutic Area: Oncology Product Name: IDE161
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Ideaya Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 31, 2022
Details:
Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001, which will be led by Dr Amit Patel’s Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester, UK.
Lead Product(s): ALETA-001
Therapeutic Area: Oncology Product Name: ALETA-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Aleta Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 23, 2021
Details:
The partnership focuses on Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist TT-702, for the treatment of multiplecancers including prostate and triple-negative breast.
Lead Product(s): TT-702
Therapeutic Area: Oncology Product Name: TT-702
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Teon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 01, 2021
Details:
BioInvent is conducting a Phase I/II trial of BI-1206 in combination with rituximab to treat NHL. CRUK decided to end the trial being conducted in the UK after the single-agent part of the study. Both parties have agreed to restructure their agreement concerning BI-1206.
Lead Product(s): BI-1206,Rituximab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: BioInvent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
Details:
The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Lead Product(s): TGL-100
Therapeutic Area: Oncology Product Name: TGL-100
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Touchlight
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 29, 2020
Details:
The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ideaya Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
